Holly Brunton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/839238/publications.pdf

Version: 2024-02-01

11	635	7	8
papers	citations	h-index	g-index
13	13	13	1620
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	FAK regulates IL-33 expression by controlling chromatin accessibility at c-Jun motifs. Scientific Reports, 2021, 11, 229.	3.3	14
2	Using Chromatin Accessibility to Delineate Therapeutic Subtypes in Pancreatic Cancer Patient-Derived Cell Lines. STAR Protocols, 2020, 1, 100079.	1.2	6
3	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Cell Reports, 2020, 31, 107625.	6.4	78
4	PDAC Subtypes/Stratification. Molecular and Translational Medicine, 2020, , 117-128.	0.4	1
5	AB001. S001. Defining DDR deficiency and replication stress in pancreatic cancer. Annals of Pancreatic Cancer, 2018, 1, AB001-AB001.	1.2	0
6	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Molecular Medicine, 2017, 9, 1011-1029.	6.9	63
7	Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell, 2016, 29, 270-284.	16.8	198
8	The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNF $\hat{\textbf{1}}\pm$. Cancer Discovery, 2014, 4, 1214-1229.	9.4	174
9	Visualisation of \hat{l}^3 H2AX Foci Caused by Heavy Ion Particle Traversal; Distinction between Core Track versus Non-Track Damage. PLoS ONE, 2013, 8, e70107.	2.5	68
10	Analysis of Human Syndromes with Disordered Chromatin Reveals the Impact of Heterochromatin on the Efficacy of ATM-Dependent G ₂ /M Checkpoint Arrest. Molecular and Cellular Biology, 2011, 31, 4022-4035.	2.3	32
11	<i>HNF4A</i> and <i>CATA6</i> Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. SSRN Electronic Journal, 0, , .	0.4	1